Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Marker Therapeutics (MRKR) EBIT Margin (2016 - 2025)

Historic EBIT Margin for Marker Therapeutics (MRKR) over the last 9 years, with Q3 2025 value amounting to 173.3%.

  • Marker Therapeutics' EBIT Margin fell 487000.0% to 173.3% in Q3 2025 from the same period last year, while for Sep 2025 it was 876.6%, marking a year-over-year increase of 10403200.0%. This contributed to the annual value of 5559.19% for FY2024, which is 51188100.0% down from last year.
  • Marker Therapeutics' EBIT Margin amounted to 173.3% in Q3 2025, which was down 487000.0% from 494.79% recorded in Q2 2025.
  • Over the past 5 years, Marker Therapeutics' EBIT Margin peaked at 93.29% during Q4 2024, and registered a low of 1320.14% during Q1 2025.
  • Over the past 4 years, Marker Therapeutics' median EBIT Margin value was 400.28% (recorded in 2022), while the average stood at 482.66%.
  • Per our database at Business Quant, Marker Therapeutics' EBIT Margin surged by 11176200bps in 2024 and then crashed by -11152500bps in 2025.
  • Over the past 4 years, Marker Therapeutics' EBIT Margin (Quarter) stood at 400.28% in 2022, then soared by 31bps to 278.06% in 2023, then soared by 134bps to 93.29% in 2024, then crashed by -286bps to 173.3% in 2025.
  • Its EBIT Margin was 173.3% in Q3 2025, compared to 494.79% in Q2 2025 and 1320.14% in Q1 2025.